 Valirx (LON:VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, said it has been granted a patent in the US for a cancer screening method,..
Proactive Investors 2 days ago
|
Valirx (LON:VAL) surged in morning trade after its full year report revealed a 157b percent jump in revenues and a significant increase in research and development (R&D) spending.
Valirx said it..
Proactive Investors 2 weeks ago
|
Cancer and personalised medicine biotech Valirx (LON:VAL) has raised £900,000 through a placing to fund ongoing pre-clinical work on its cancer treatments and pipeline projects.
Six Valirx..
Proactive Investors on April 3, 2012
|
Valirx Plc (LON:VAL) has completed what it calls a material transfer agreement which will see the Institut Paoli & Calmettes in Marseille carry out translational and developmental studies on the..
Proactive Investors on March 30, 2012
|
Valirx’s (LON:VAL) lead drug candidate may have an important role to play in the treatment of refractory prostate cancer.
This was one of the conclusions of a review by independent experts..
Proactive Investors on March 8, 2012
| Life science firm Valirx (LON:VAL) has established a scientific advisory board (SAB) to support the next steps in the development of its technologies and products in cancer therapeutics and..
Proactive Investors on February 14, 2012
|
Glencore approach to Xstrata lifts mining sector, but results from Unilever disappoint
On a busy day for corporate news, *Vodafone* was one of the big risers after an Indian court ruling appeared to..
guardian.co.uk on February 2, 2012
|
Valirx (LON:VAL) shares shot up around 35 per cent after the unexpected news that a newly acquired screening product for skin cancer had been granted a European patent.
The test is for a..
Proactive Investors on February 2, 2012
|
Global 
73.0°F • Ontario, CA
U.S. version
